Neuroscience News

A new study from Knight Initiative researchers suggests that the two-dose shingles shot also may slow the progression of dementia

A Knight Initiative-funded project says shingles vaccination could protect you from getting dementia or slow the progression of the disease

Knight Initiative scientists report that biology, behavior, and circumstance all intertwine over a lifetime to influence how organs grow old

Everything we know now, and what we hope and pray is coming

Amyotrophic lateral sclerosis and frontotemporal dementia are devastating neurodegenerative diseases. Knight Initiative postdoc Yi Zeng is working to understand the role a central protein plays in both diseases—and whether it might point toward new diagnostics and treatments

Neuroradiologist Raag Airan and his lab have found a non-invasive, drug-free method to help clean the brain, reduce inflammation, and treat disease—and with Knight Initiative for Brain Resilience support, they plan to test it in people soon.

The Knight Initiative’s Fall Symposium featured researchers building new molecular atlases of the brain alongside new updates on neurodegenerative disease and what might be done about it.

Research from Knight Initiative Director Tony Wyss-Coray's lab show that an Alzheimer's hallmark—myriad oily droplets in brain cells called microglia—may help connect several of the disorder’s better known but not well understood features.

Neurons are built to last, but with age, bad things can happen to them. Wu Tsai Neuro affiliate Katrin Andreasson's work shows a lot of it is triggered by what’s happening to immune cells outside of the brain.

A new study led by Wu Tsai Neuro Faculty Scholar Laura Gwilliams maps how we simultaneously process different words.

In which we discuss how bad social isolation is for our brains with neuroscientist and author Ben Rein

Organizers of the Wu Tsai Neurosciences Institute’s 12th annual symposium share exciting new discoveries from the frontiers of the “gut-brain axis.”

Amyloid plaques have long been the focus of Alzheimer’s therapies. But Wu Tsai Neuro's Emmanuel Mignot and others are focusing on the stringy tangles of a protein called tau, the unsung second hallmark of Alzheimer’s.

The genetic variant APOE4, carried by one-fifth of the world’s people, substantially boosts Alzheimer’s risk. But scientists have been puzzled about how to reverse that risk: punch up the gene variant’s potency, or smack it down? Now we know, thanks to research funded by the Knight Initiative for Brain Resilience.

Researchers from around the university will collaborate to deepen our understanding of the brain.

Stanford's Office of Postdoctoral Affairs has named Hulya Torun one of this year's Postdoc Champions